Figure 1: COMET study planned enrollment flowchart.

Older adult diagnosed with probable Alzheimer’s disease at a participating Memory Care Practice
N=500

Excluded due to:
Inclusion / exclusion criteria
Refusal
Other

Consent and Baseline assessment
N=300

Randomization by Patient
Stratified by Memory Care Practice

Allocated to donepezil
N=100

Allocated to rivastigmine
N=100

Allocated to galantamine
N=100

Follow-up assessment at 6, 12, and 18 weeks